Skip to main content

Table 3 Expression of LL-37 transcript in non-adherent lymphocytes in healthy adults before and after supplementation

From: Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis

  

LL-37 transcript (copy no.)

  

Day-0

Day-4

Day-8

Group-I

NAL

9.60 ± 2.80

19.5 ± 7.65

7.46 ± 5.00

Group-II

NAL

29.57 ± 6.17

54.43 ± 16.48

38.25 ± 20.66

Group-III

NAL

19.33 ± 8.21

30.00 ± 10.60

20.00 ± 5.01

Group-IV

NAL

14.78 ± 3.08

18.68 ± 5.92

19.12 ± 10.33

Group-V

NAL

9.18 ± 2.39

23.30 ± 14.58

20.71 ± 7.45

  1. Note. Group-I: 250 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-II: 500 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-III: 1000 mg PB b.d. + 5000 IU vitamin D3 o.d.; Group-IV: 500 mg PB b.d.; Group-V: 5000 IU vitamin D3 o.d. Data expressed as Mean ± Standard Deviation. One Way Analysis of Variance (ANOVA) method was used. Analysis of Co-variance was performed when significant difference was found at entry level. PB, Phenylbutyrate; NAL, Non-adherent lymphocytes; b.d., Twice daily; o.d., Once daily.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us